KR20180070342A - Composition for preventing or treating of allergy comprising mixture of probiotics as an active ingredient - Google Patents

Abstract

The present invention relates to a composition, comprising a probiotics mixed strain as an active ingredient, for preventing, alleviating, or treating allergy. Inventors of the present invention have identified that a probiotics mixed strain, prepared by mixing two or more kinds selected from Lactococcus lactis KF140, Pediococcus pentosaceus KF159, Lactobacillus pentosus KF340, Lactobacillus paracasei 698, and Bacillus amyloliquefaciens 26N strains, has excellent activity for suppressing allergies by observing that the probiotics mixed strain exhibits, in a food allergy model, the effects of reducing symptoms caused by food allergy, reducing secretion of IgE in blood, reducing cytokine associated with Th2 and Th17, and increasing cytokine associated with Th1. According to the present invention, the mixed strain is expected to be advantageously used in pharmaceuticals, health function foods, and cosmetics for preventing, alleviating, or treating allergies.

Description

TECHNICAL FIELD The present invention relates to a composition for prevention or treatment of allergy comprising a probiotic mixed strain as an active ingredient,

The present invention relates to a composition for prevention, improvement or treatment of allergy, which comprises a probiotic mixed strain as an active ingredient.

Allergy is a disease caused by a malfunction of the immune system that causes irritation such as urticaria, itching, runny nose, and cough in a specific person. It is a disease caused by environmental pollution, westernization of diet and lifestyle, Environmental factors such as stress, genetics, and various allergens. The prevalence rate is increasing worldwide, and 20 to 25% of all people suffer from allergic diseases such as rhinitis, asthma, atopic dermatitis, and food allergy.

Allergic reactions are traditionally divided into four classes based on the time and type of expression: type I-type III is a humoral immune response (immediate type) involving antibodies, type IV is a cell-mediated immune response Delay type). Most allergic reactions are type I, and are typical diseases such as asthma, rhinitis, conjunctivitis, food and drug allergy, and atopic dermatitis. In severe cases, anaphylaxis may occur.

Currently, most medicines for the treatment of allergy are focused on suppressing the secretion of histamine secreted in the last stage of the allergy mechanism or treating the symptoms caused by allergy, and there are few therapeutic agents showing definite effects. The treatment of allergic diseases can be done for a long period of time. Most of the drugs with excellent therapeutic effect are widely used for atopic dermatitis, allergic rhinitis and asthma as long as they are steroid drugs. However, long term use can cause serious side effects. Antihistamines also cause symptoms to feel alleviated, but long-term use causes side effects such as depression, concentration difficulties, lethargy, drowsiness, and hepatic disorders, and the problem of recurrence of allergic diseases is discontinued. Furthermore, since allergic diseases, especially atopic dermatitis, are mostly in children and adolescents, it is very important to develop a safe therapeutic agent free from toxicity and side effects, and researches to overcome these limitations are actively conducted. However, It is not easy.

Recently, the metagenome project to identify intestinal bacterial pathogens in the United States has revealed the correlation between the distribution of intestinal microflora and various immune system diseases including allergies. Thus, the distribution and diversity of intestinal bacteria and intestinal immunity are closely related to the immune system.

Probiotics is defined as a live microorganism that has beneficial effects on the health of the host when ingested in an appropriate amount (FAO / WHO). Looking at the probiotic market, the world probiotics market will reach 35 trillion won by 2014, And 7.6%, respectively. The domestic probiotic market is expected to reach 150 billion won by 2014, but the market is growing rapidly, with a 250% growth rate from 2013.

Currently, the evaluation of immunity control for overseas probiotics is applied to various disease animal models, and the results are also increasing at a rapid pace every year. In addition to targeting inflammatory responses to inflammatory diseases such as Type 1 diabetes, rheumatoid arthritis, degenerative arthritis, and ulcerative colitis, a probiotic that can increase the immune response to fight against diseases such as influenza virus or cancer Research is actively underway on the function of In addition, the role of probiotics and their functions are attracting much attention for the prevention and treatment of diseases such as allergy, asthma and atopy.

Since most probiotics are derived from human intestines or foods, there is an advantage in that there is no major problem in proving stability with other chemical agents once the efficacy has been demonstrated using animal models. In recent years, the therapeutic effect of probiotics as an immunomodulatory agent has been verified through various clinical trials. Many diseases such as asthma, ulcerative colitis, and arthritis have been tried, and clinical trials and studies on atopy have been accelerated (KR 10-1355440).

Accordingly, the inventors of the present invention have found a mixed bacterial strain of probiotics having an excellent allergic inhibitory activity using probiotics having the above-mentioned advantages, thereby completing the present invention.

The present inventors have studied the composition of probiotics capable of effectively preventing or treating allergic diseases. As a result, they have found that a mixed strain according to the present invention, more preferably Lactococcus lactis KF140 strain (Accession No. KCCM 11673P), Pediococcus A strain of Pediococcus pentosaceus KF159 (Accession No. KCCM 11674P), a strain of Lactobacillus pentosus KF340 (Accession No. KCCM 11675P), a strain of Bacillus amyloliquefaciens 26N (KCCM 11287P), and Lactobacillus paracasei 698 (Accession No. KFCC 11569P) were administered to a food allergy mouse model, the excellent allergic inhibitory activity The present invention has been completed.

Accordingly, it is an object of the present invention to provide a composition for prevention, improvement, or treatment of allergy, comprising a probiotic mixed strain of the above-mentioned constitution or a culture of the mixed strain as an active ingredient.

However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.

In order to achieve the object of the present invention, the present invention provides a strain of Lactococcus lactis KF140 (Accession No. KCCM 11673P), a strain of Pediococcus pentosaceus KF159 (accession number: KCCM 11674P), Lactobacillus pentosus KF340 (Accession No. KCCM 11675P), Bacillus amyloliquefaciens 26N (Accession No. KCCM 11287P), and Lactobacillus paracase 698 Lactobacillus paracasei 698) (Accession No. KFCC 11569P), or a culture of the above-mentioned mixed strain as an active ingredient. The present invention also provides a pharmaceutical composition for preventing or treating allergy.

The present invention also provides a method for producing Lactococcus lactis KF140 (Accession No. KCCM 11673P), Pediococcus pentosaceus KF159 (Accession No. KCCM 11674P), Lactobacillus pentosaceus KF340 Lactobacillus pentosus KF340) (Accession No. KCCM 11675P), Bacillus amyloliquefaciens 26N (Accession No. KCCM 11287P), and Lactobacillus paracasei 698 (Accession No. KFCC 11569P ) Or a culture of the above-mentioned mixed strains as an active ingredient. The present invention also provides a health functional food composition for alleviating allergies.

The present invention also provides a method for producing Lactococcus lactis KF140 (Accession No. KCCM 11673P), Pediococcus pentosaceus KF159 (Accession No. KCCM 11674P), Lactobacillus pentosaceus KF340 Lactobacillus pentosus KF340) (Accession No. KCCM 11675P), Bacillus amyloliquefaciens 26N (Accession No. KCCM 11287P), and Lactobacillus paracasei 698 (Accession No. KFCC 11569P ) Or a culture of the above-mentioned mixed strain as an active ingredient. The present invention also provides a cosmetic composition for improving allergy.

In one embodiment of the present invention, the mixed strain is a strain of Pediococcus pentosaceus KF159 (Accession No. KCCM 11674P) and a strain of Lactobacillus pentosus KF340 (Accession No. KCCM 11675P) . ≪ / RTI >

In another embodiment of the present invention, the mixed strain is a strain of Pediococcus pentosaceus KF159 (Accession No. KCCM 11674P), a strain of Lactobacillus pentosus KF340 (Accession No. KCCM 11675P) , And Bacillus amyloliquefaciens 26N (Accession No. KCCM 11287P).

In another embodiment of the present invention, the mixed strain is selected from the group consisting of Lactococcus lactis KF140 (Accession No. KCCM 11673P), Pediococcus pentosaceus KF159 (Accession No. KCCM 11674P ), Lactobacillus pentosus KF340 (Accession No. KCCM 11675P), and Bacillus amyloliquefaciens 26N (Accession No. KCCM 11287P).

In another embodiment of the present invention, the mixed strain is selected from the group consisting of Lactococcus lactis KF140 (Accession No. KCCM 11673P), Pediococcus pentosaceus KF159 (Accession No. KCCM 11674P ), Lactobacillus pentosus KF340 (Accession No. KCCM 11675P), Bacillus amyloliquefaciens 26N (Accession No. KCCM 11287P), and Lactobacillus paracasei 698) strain (Accession No. KFCC 11569P).

In another embodiment of the present invention, the composition can inhibit diarrhea reaction, anaphylactic reaction, and rectal temperature decrease due to food allergy.

In another embodiment of the present invention, the composition may inhibit the production of immunoglobulin E (IgE).

In another embodiment of the present invention, the composition may inhibit Th2-related cytokine and Th17-related cytokine production.

In another embodiment of the present invention, the composition may increase Thl-related cytokine production.

The present invention also provides a method of preventing or treating an allergy, comprising the step of administering the pharmaceutical composition to a subject.

The present invention also provides the use of the pharmaceutical composition for the prevention or treatment of allergy.

The inventors of the present invention prepared by mixing two or more kinds selected from Lactococcus lactis KF140, Pediococcus pentosaceus KF159, Lactobacillus pentosus KF340, Lactobacillus paracasei 698, and Bacillus amyloliquefaciens strain 26N One probiotic mixed strain has excellent allergic inhibitory activity in the food allergy model by observing that it decreases the symptoms caused by food allergy, decreases the secretion of blood IgE, decreases the production of Th2 and Th17 related cytokine, and increases Th1-related cytokine production As a result, it is expected that the above-mentioned mixed strain according to the present invention can be usefully used in the fields of pharmaceuticals, health functional foods, and cosmetics for the prevention, improvement, or treatment of allergy.

FIG. 1 is a diagram illustrating the production of a food allergy model and a protocol for administering a strain.
FIGS. 2A to 2C are graphs showing the results of a food allergy mouse model in which a food allergic mouse model was administered with a mixture of two kinds (two kinds), three kinds (three kinds), four kinds (four kinds) (Fig. 2a), anaphylactic reaction (Fig. 2b), and rectal temperature reduction (Fig. 2c).
FIGS. 3A to 3C are graphs showing the effect of the Th2-related cytokine, IL-4, on the food allergic mouse model after the administration of two kinds of blend (P2), three kinds of mixture (P3), four kinds of mixture (P4) (Figure 3a), IL-10 (Figure 3b), and IL-13 (Figure 3c) levels.
FIGS. 4A to 4C are graphs showing the results obtained by using each of the sole strains, ie, Bacillus amyloliquefaciens 26N (26), Lactococcus lactis KF140 (140), Lactobacillus pentosus KF340 (340) (Fig. 4A), anaphylactic reaction (Fig. 4B), and rectal temperature reduction (Fig. 4C) after administration of the strain.
FIGS. 5A to 5C show the results of inhibition of diarrhea (FIG. 5A), anaphylactic reaction (FIG. 5B), and reduction of rectal temperature (FIG. 5C) after administration of a five-component mixed strain (P5) and dexamethasone .
FIGS. 6A and 6B are the results of measurement of total serum IgE (FIG. 6A) and ovalbumin-specific IgE (FIG. 6B) content in the food allergy model mice according to the administration of the five mixed strains.
7a, 7b), IL-5 (Fig. 7b), Thl, Thl, and Th17 -related cytokines in the mesenteric lymph node culture supernatant upon administration of the five mixed strains in food allergy model mice. (Figure 7c), IL-13 (Figure 7d), IFN-y (Figure 7e), and IL-17 (Figure 7f).

The present invention relates to a composition for prevention, improvement or treatment of allergy, which comprises a probiotic mixed strain as an active ingredient.

Hereinafter, the present invention will be described in detail.

The present invention relates to a strain of Lactococcus lactis KF140 (Accession No. KCCM 11673P), a strain of Pediococcus pentosaceus KF159 (Accession No. KCCM 11674P), a strain of Lactobacillus pentosus (Accession No. KFCC 11569P), a strain of Bacillus amyloliquefaciens 26N (Accession No. KCCM 11287P), and a strain of Lactobacillus paracasei 698 (Accession No. KFCC 11569P) And a pharmaceutical composition for preventing or treating allergy comprising as an active ingredient at least two kinds of mixed strains selected from the group consisting of the above strains or a culture of the above mixed strains.

As used herein, the term " prophylactic " means any action that inhibits or slows the onset of an allergic disease by administration of the pharmaceutical composition according to the present invention.

The term " treatment " as used in the present invention means all the actions for alleviating or alleviating symptoms of allergic diseases by administration of the pharmaceutical composition according to the present invention.

The term " probiotics " used in the present invention refers to living microorganisms which have beneficial effects on the health of a host when consumed at an appropriate dose, and bifid bacteria and lactic acid bacteria are typically known. In addition, it proliferates in the intestines and gives beneficial effect to human body. It is recognized as probiotics if it is non-pathogenic and does not have toxicity.

In the present invention, the probiotic mixed strains may be contained in the same amount, but are not limited thereto, and the 16S rDNA sequences of the respective deposited strains are represented by SEQ ID NOS: 1-5.

In the present invention, the above-mentioned mixed strain comprises a strain of Pediococcus pentosaceus KF159 (Accession No. KCCM 11674P) and a strain of Lactobacillus pentosus KF340 (Accession No. KCCM 11675P) Lt; / RTI >

In addition, the above-mentioned mixed strains may be selected from the group consisting of Pediococcus pentosaceus KF159 (Accession No. KCCM 11674P), Lactobacillus pentosus KF340 (Accession No. KCCM 11675P), and Bacillus amyloliquefine And a strain of Bacillus amyloliquefaciens 26N (accession number KCCM 11287P).

In addition, the above-mentioned mixed strains include strains of Lactococcus lactis KF140 (Accession No. KCCM 11673P), Pediococcus pentosaceus KF159 (Accession No. KCCM 11674P), Lactobacillus pentosaceus KF340 , A strain of Lactobacillus pentosus KF340 (Accession No. KCCM 11675P), and a strain of Bacillus amyloliquefaciens 26N (Accession No. KCCM 11287P).

In addition, the above-mentioned mixed strains include strains of Lactococcus lactis KF140 (Accession No. KCCM 11673P), Pediococcus pentosaceus KF159 (Accession No. KCCM 11674P), Lactobacillus pentosaceus KF340 (Lactobacillus pentosus KF340) strain (Accession No. KCCM 11675P), Bacillus amyl Lowry kwipe sieon's 26N (Bacillus amyloliquefaciencs 26N) strain (Accession No. KCCM 11287P), and Lactobacillus para casei 698 (Lactobacillus paracasei 698) strain (Accession No. KFCC 11569P). ≪ / RTI >

In the examples of the present invention, antiallergic activity by the mixed strains was evaluated through various experiments using a food allergy mouse model.

In one embodiment of the present invention, a mixed strain of a mixture of two, three, four, and five species of the present invention is administered to a food allergy mouse model, and then the diarrhea reaction, anaphylactic reaction, The IL-4, IL-10, and IL-13 levels, which are Th2-related cytokines, were also observed to decrease as the number of mixed strains increased (Example 2 Reference).

In another embodiment of the present invention, in the food allergic mouse model, five mixed strains according to the present invention and the sole strains Bacillus amyloliquefaciens 26N (26), Lactococcus lactis KF140 (140) and As a result of comparing the degrees of alleviation of food allergy symptoms with Lactobacillus pentosus KF340 strain (340), it was confirmed that diarrhea reaction, anaphylactic reaction, and rectal temperature reduction inhibitory activity were highest when 5 mixed strains were administered (Example 3 Reference).

In another embodiment of the present invention, the effect of alleviating the food allergic symptoms of dexamethasone, an immunosuppressive agent used as an agent for treating allergic diseases, and the five mixed strains of the present invention were compared with each other, In addition, we confirmed the effect of the mixed strains on alleviating the excellent food allergic symptoms, and also showed an effective reduction of total IgE and anti-albumin antigen-specific IgE in the blood, Th1 / Th2 balance control effect by reduction of Th2 and Th17 related cytokine and Th1 cytokine (See Example 4).

Therefore, the probiotic mixed strains of the present invention can be usefully used for prevention, improvement, or treatment of allergy.

The pharmaceutical composition according to the present invention may further comprise a pharmaceutically acceptable carrier comprising the probiotic mixed strain or a culture thereof as an active ingredient. Such pharmaceutically acceptable carriers are those conventionally used in the field of application and include, but are not limited to, saline, sterile water, Ringer's solution, buffered saline, cyclodextrin, dextrose solution, maltodextrin solution, glycerol, ethanol, And may further contain other conventional additives such as antioxidants and buffers as needed. It may also be formulated into injectable formulations, pills, capsules, granules or tablets, such as aqueous solutions, suspensions, emulsions and the like, with the addition of diluents, dispersants, surfactants, binders and lubricants. Suitable pharmaceutically acceptable carriers and formulations can be suitably formulated according to the respective ingredients using the methods disclosed in Remington's reference. The pharmaceutical composition of the present invention is not particularly limited to a formulation, but may be formulated into injections, inhalants, external skin preparations, and the like.

The pharmaceutical composition of the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) depending on the intended method, and the dose may vary depending on the condition and the weight of the patient, The mode of administration, the route of administration, and the time, but may be appropriately selected by those skilled in the art.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, " pharmaceutically effective amount " means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment. The effective dose level is determined depending on the type of disease, severity, The time of administration, the route of administration and the rate of excretion, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts. The pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, sequentially or concurrently with conventional therapeutic agents, and may be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.

Specifically, the effective amount of the pharmaceutical composition of the present invention may vary depending on the age, sex, condition, body weight, the degree of absorption of the active ingredient in the body, the rate of inactivation and the excretion rate, the type of disease, 0.001 to 150 mg, preferably 0.01 to 100 mg per kg of body weight, may be administered daily or every other day, or one to three divided doses per day. However, the dosage may be varied depending on the route of administration, the severity of obesity, sex, weight, age, etc. Therefore, the dosage is not limited to the scope of the present invention by any means.

In another aspect of the present invention, the present invention provides a health functional food composition for alleviating allergies comprising the probiotic mixed strain or a culture thereof as an active ingredient.

As used herein, the term "improvement" means all actions that at least reduce the degree of symptom associated with the condition being treated. At this time, the health functional food composition may be used either simultaneously with or separately from the agent for treatment before or after the onset of the disease for the prevention or improvement of the allergy disease.

The term " health functional food composition " as used in the present invention means any one or more selected from the group consisting of tablets, pills, powders, powders, capsules, and liquid formulations including one or more of carriers, diluents, excipients, Which is characterized in that it is formulated into one. Examples of foods that can be added to the mixed strain composition of the present invention include various foods, powders, granules, tablets, capsules, syrups, beverages, gums, tea, vitamin complexes, and health functional foods. Examples of the additive that can be further included in the present invention include natural carbohydrates, flavors, nutrients, vitamins, minerals (electrolytes), flavors (synthetic flavors, natural flavors and the like), colorants, fillers, At least one component selected from alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, antioxidants, glycerin, alcohols, carbonating agents and fats can be used. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. As the above-mentioned flavors, natural flavors (tautatin, stevia extract (for example, rebaudioside A and glycyrrhizin) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used. The composition according to the present invention can be used in various forms such as flavorings such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and heavies, factic acid and its salts, alginic acid and its salts, , pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, etc. Other compositions according to the present invention may contain flesh for the production of natural fruit juices and vegetable drinks . These components may be used independently or in combination. Specific examples of the carrier, excipient, diluent, and additive include, but are not limited to, lactose, dextrose But are not limited to, sucrose, sorbitol, mannitol, erythritol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium phosphate, calcium silicate, microcrystalline cellulose, polyvinylquilolidone, cellulose, polyvinylpyrrolidone, methylcellulose, water , At least one selected from the group consisting of sugar syrup, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil is preferably used.

As another embodiment of the present invention, the present invention provides a cosmetic composition for improving allergy comprising the probiotic mixed strain or a culture thereof as an active ingredient.

The cosmetic composition of the present invention may contain not only probiotic mixed strains or cultures thereof, but also components commonly used in cosmetic compositions, such as antioxidants, stabilizers, solubilizers, vitamins, pigments, Such as conventional adjuvants, and carriers.

In addition, the composition of the present invention may be used in combination with the organic UV-blocking agent that has been used in the past, in addition to the probiotic mixed strain or the culture thereof, so long as it does not impair the skin protecting effect. Examples of the organic UV blocking agent include glyceryl paraben, drometrizol trisiloxane, drometrizol, dipaloyyl triolate, disodium phenyldibenzimidazole tetrasulfonate, diethylhexylbutamidotriazone, diethylamino Hydroxybenzoylhexyl benzoate, di-methoxycinnamate, a mixture of Rawson and dihydroxyacetone, methylene bis-benzotriazolyltetramethylbutylphenol, 4-methylbenzylidene camphor, menthyl anthranylate, benzophenone (Benzophenone-4), benzophenone-8 (dioxyphenylbenzone), butylmethoxydibenzoylmethane, bisethylhexyloxyphenol methoxyphenyltriazine, synoxate, ethyl dihydroxypropylparaben, Ethylhexyldimethylpivalate, ethylhexylmethoxycinnamate, ethylhexylsalicylate, ethylhexyltriazone, isoamyl-p-methoxy cinnamate, polysilicon-15 (dimethicodimethylbenzalmate, At least one selected from the group consisting of terephthalylidene dicam peresophilic acid and its salts, thiai-salicylate and aminobenzoic acid (parabe) can be used.

Examples of products to which the cosmetic composition of the present invention can be added include cosmetics such as astringent lotion, softening longevity lotion, nutrition lotion, various creams, essences, packs, foundation and the like, cleansing, cleanser, soap, . Specific formulations of the cosmetic composition of the present invention include skin lotions, skin softeners, skin toners, astringents, lotions, milk lotions, moisturizing lotions, nutritional lotions, massage creams, nutritional creams, moisturizing creams, hand creams, essences, It includes formulations such as soap, shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, latex, lipstick, makeup base, foundation, press powder, loose powder, eye shadow and the like.

According to a preferred embodiment of the present invention, the content of the probiotic mixed strain or the culture thereof of the present invention is 0.00001-30% by weight, preferably 0.5-20%, more preferably 1.0-10 Weight%. If the content of the probiotic mixed strain or the culture thereof is less than 0.00001% by weight, the effect of absorbing ultraviolet light is greatly reduced. If the content is more than 30% by weight, skin irritation may be caused.

Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the following examples.

[Example]

Example 1. Experimental Preparation and Experimental Method

1-1. Strain isolation and identification

The strains for producing the probiotic mixture of the present invention were isolated and identified by the following method. More specifically, strains of Lactococcus lactis KF140, Pediococcus pentosaceus KF159, Lactobacillus pentosus KF340 and Lactobacillus paracasei 698 were identified by MRS Bacillus amyloliquefaciencs strain 26N was isolated from TSB agar medium (TSB medium, BD236950, Difco, USA), and was isolated from a kimchi prepared by using a conventional agar medium (MRS medium, BD288130, USA). As a result, 16S rDNA of 26S strain of Bacillus amyloliquefaciens showed 100% homology with the existing strain of Bacillus amyloliquefaciens FZB42 (T). As a result, The Lactococcus lactis KF140 strain was found to have a homology of 99.8% with the conventional Lactococcus lactis NCDO604 (T) strain and the Pediococcus pentosaceus KF159 strain with the existing Pediococcus pentosaceus DSM20336 (T) strain And 99.52%, Lactobacillus pentosus KF340 strain was 99.73% homologous with the conventional Lactobacillus pentosus JCM1558 (T) strain, and Lactobacillus paracasei 698 strain was the Lactobacillus paracase strain JCM1171 And 99.88%, respectively.

The Bacillus amyloliquefaciens strain 26N was stably incubated in TSB agar medium at pH 6.5 ± 0.2, 37 ° C., and 24 hours, and each of the remaining four strains was cultured on MRS agar medium at pH 6.5 ± 0.2, 37 ° C., And cultured for 48 hours. All of the above five strains were anaerobically anaerobically anaerobically oxygenated, and had the characteristics of being able to preserve the strain through freeze-drying preservation or cell suspension freezing. The strains were deposited with the Korean Microorganism Conservation Center (KCCM) The deposit numbers are shown in Table 1 below.

Strain name Accession number Lactococcus lactis KF140 KCCM 11673P Pediococcus pentosaceus KF159 KCCM 11674P Lactobacillus pentosus KF340 KCCM 11675P Bacillus amyloliquefaciencs 26N KCCM 11287P Lactobacillus paracasei 698 KFCC 11569p

1-2. Production of food allergy model and strain administration

5-week-old magnetic BALB / c mice were supplied from Orient Bio Inc., and were used for breeding and purification for one week in an experimental animal room. As shown in FIG. 1, 100 μl of 20 μg of ovalbumin (OVA) and 2 mg of alum mixed solution was intraperitoneally administered to each mouse, and after 14 days, the mice were immunized by the same method Secondary immunization was performed. After 14 days of the second immunization, the probiotics mixture was administered daily at a concentration of 5 × 10 ⁸ CFU per day. The composition and dosage of the detailed strains used in this Example are summarized in Table 2 below. At this time, as a normal control group, the same amount of PBS as a suspension medium was administered in place of the probiotic suspension, and a positive control [PC (daxa)] was administered the immunosuppressant dexamethasone. In order to induce food allergy, OVA of 50 ㎎ / mouse / day was orally administered to all groups at intervals of 3 days from the 14th day after the second immunization. After an oral administration of OVA, the anaphylactic reaction and diarrhea reaction, which are food allergy inducing indicators, were observed at intervals of 30 minutes. Changes in rectal temperature were measured at intervals of 20 minutes for 60 minutes.

Groups Strain combination Concentration per strain Mixed strain concentration 26 26 5 x 10 < ⁸ > CFU / day - 140 140 5 x 10 < ⁸ > CFU / day - 340 340 5 x 10 < ⁸ > CFU / day - Two species (P2) 340 + 159 2.5 x 10 < ⁸ > CFU / day 5 x 10 < ⁸ > CFU / day Three species (P3) 340 + 159 + 26 1.7 x 10 < ⁸ > CFU / day 5 x 10 < ⁸ > CFU / day Four species (P4) 340 + 159 + 26 + 140 1.25 x 10 < ⁸ > CFU / day 5 x 10 < ⁸ > CFU / day Mix of 5 species (P5) 340 + 159 + 140 + 26 + 698 1 x 10 < ⁸ > CFU / day 5 x 10 < ⁸ > CFU / day

Example 2. Comparative inhibition activity of food allergen according to composition of probiotic mixed strain

In order to analyze the food allergic activity of the probiotic mixed strains in the food allergic mouse model produced according to the method of Example 1-2, as shown in Table 2, a mixture of two (P2), three (P3), and three The degree of alleviation of food allergy symptoms such as diarrhea reaction, anaphylactic reaction, and rectal temperature reduction by 4 kinds of mixed (P4) and 5 kinds of mixed (P5) strains were compared. As a result, as shown in Figs. 2 (a) to 2 (c), the effect of alleviating the symptoms of food allergy was increased as the number of mixed strains was increased. Especially, In case of administration of the species mixed strain, it was confirmed that the food allergy symptom was most suppressed.

Next, levels of IL-4, IL-10, and IL-13, which are Th2-related cytokines involved in induction and persistence of allergic responses, were measured. As a result, as shown in FIG. 3A to FIG. 3C, the level of the cytokines decreased with increasing number of mixed strains, and it was confirmed that the number of the cytokines decreased most when the mixed strains were administered.

Example 3. Comparison of inhibitory activity of food allergies between probiotics alone and five mixed strains

Based on the results of Example 2, the present inventors compared the activity of inhibiting the food allergies of each single strain constituting the 5-species mixed strain and the 5-species mixed strain of the present invention. For this, experiments were conducted according to the methods of Examples 1-2 and 2 to measure the degree of alleviation of food allergy symptoms. As a result, as shown in Figs. 4A to 4C, when the five mixed strains were administered, each single strain, i.e., Bacillus amyloliquefaciens 26N (26), Lactococcus lactis KF140 (140), and Lactobacillus pento It was confirmed that diarrhea, anaphylactic reaction, and rectal temperature reduction inhibition activity were the highest in food allergy - induced diarrhea compared to SUS KF340 (340).

Example 4. Confirmation of food allergy inhibitory activity of a mixed strain of five probiotics

4-1. Check for alleviation of food allergy symptoms

Based on the results of Examples 2 and 3, the present inventors compared the effects of dexamethasone, an immunosuppressive agent used as a therapeutic agent for allergic diseases, in order to confirm the allergen-suppressing activity of a mixed culture of five probiotics according to the present invention. For this, as shown in FIGS. 5A to 5C, the degree of alleviation of food allergy symptoms according to the method of Example 1-2 was slightly lower than that of the positive control group, Diarrhea, and anaphylactic reactions and relieved the degree of reduction of rectal temperature induced by allergy.

4-2. Confirmation of IgE secretion inhibition

In addition to the above results, in order to measure the blood IgE content in the food allergy model mice after the administration of the 5 kinds of mixed strains, the blood was collected through the mouse orbital vein and centrifuged at 3500 rpm for 10 minutes to separate the serum. Then, total IgE and ovalbumin-specific IgE (ova-specific IgE) contents of serum were measured using a mouse IgE quantitation kit of BD Co. using the separated serum.

As a result, as shown in Figs. 6A and 6B, it was confirmed that the content of total IgE and ovalbumin-specific IgE, which are closely related to allergic symptoms, was effectively reduced by the administration of the five mixed strains.

4-3. Identification of cytokine changes

In order to analyze the cytokine changes by the mixed culture of five species in the food allergy mouse model, the mesenteric lymph nodes (MLN) and the spleen were isolated from each group of mice and single celled cells were seeded in a 96 well plate at 5 × 10 ⁶ well / Respectively. After the cells were treated with 20 ㎍ of OVA for 72 hours, the supernatant was recovered and ELISA was performed using a BD cytokine quantitation kit to determine various cytokine contents.

As a result, as shown in FIGS. 7A to 7F, the Th2-related cytokine (IL-4, 5, 10, 13) and the Th17-related cytokine It was confirmed that secretion of cytokine IL-17 was significantly reduced. On the other hand, IFN-γ, a Th1 cytokine that can regulate the immune response biased by Th2 response, was increased by the combination of five strains. These results indicate that the five mixed strains have a food allergy inhibitory activity by controlling the balance of the Th1 / Th2 immune response.

It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the invention. There will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive.

<110> KOREA FOOD RESEARCH INSTITUTE <120> Composition for preventing or treating of allergy comprising          mixture of probiotics as an active ingredient <130> MP16-478 <160> 5 <170> KoPatentin 3.0 <210> 1 <211> 1490 <212> DNA <213> Lactococcus lactis KF140 16S rDNA <400> 1 tgatcatggc tcaggacgaa cgctggcggc gtgcctaata catgcaagtt gagcgctgaa 60 ggttggtact tgtaccgact ggatgagcag cgaacgggtg agtaacgcgt ggggaatctg 120 cctttgagcg ggggacaaca tttggaaacg aatgctaata ccgcataaaa actttaaaca 180 caagttttaa gtttgaaaga tgcaattgca tcactcaaag atgatcccgc gttgtattag 240 ctagttggtg aggtaaaggc tcaccaaggc gatgatacat agccgacctg agagggtgat 300 cggccacatt gggactgaga cacggcccaa actcctacgg gaggcagcag tagggaatct 360 tcggcaatgg acgaaagtct gaccgagcaa cgccgcgtga gtgaagaagg ttttcggatc 420 gtaaaactct gttggtagag aagaacgttg gtgagagtgg aaagctcatc aagtgacggt 480 aactacccag aaagggacgg ctaactacgt gccagcagcc gcggtaatac gtaggtcccg 540 agcgttgtcg ggatttattg ggcgtaaagc gagcgcaggt ggtttattaa gtctggtgta 600 aaaggcagtg gctcaaccat tgtatgcatt ggaaactggt agacttgagt gcaggagagg 660 agagtggaat tccatgtgta gcggtgaaat gcgtagatat atggaggaac accggtggcg 720 aaagcggctc tctggcctgt aactgacact gaggctcgaa agcgtgggga gcaaacagga 780 ttagataccc tggtagtcca cgccgtaaac gatgagtgct agatgtaggg agctataagt 840 tctctgtatc gcagctaacg caataagcac tccgcctggg gagtacgacc gcaaggttga 900 aactcaaagg aattgacggg ggcccgcaca agcggtggag catgtggttt aattcgaagc 960 aacgcgaaga accttaccag gtcttgacat actcgtgcta ttcctagaga taggaagttc 1020 cttcgggaca cgggatacag gtggtgcatg gttgtcgtca gctcgtgtcg tgagatgttg 1080 ggttaagtcc cgcaacgagc gcaaccccta ttgttagttg ccatcattaa gttgggcact 1140 ctaacgagac tgccggtgat aaaccggagg aaggtgggga tgacgtcaaa tcatcatgcc 1200 ccttatgacc tgggctacac acgtgctaca atggatggta caacgagtcg cgagacagtg 1260 atgtttagct aatctcttaa aaccattctc agttcggatt gtaggctgca actcgcctac 1320 atgaagtcgg aatcgctagt aatcgcggat cacacgccgc ggggttgaat acgttcccgg 1380 gccttgtaca caccgcccgt cacaccacgg gagttgggag tacccgaagt atgttgccta 1440 accgcaaagg agggcgcttc ctaaagtaag accgatgact gggggtgaag 1490 <210> 2 <211> 1402 <212> DNA <213> Pediococcus pentosaceus KF159 16S rDNA <400> 2 cgcggcatgc tgatccgcga ttactagcga ttccgacttc gtgtaggcga gttgcagcct 60 acagtccgaa ctgagaatgg ttttaagaga ttagcttaac ctcgcggtct cgcgactcgt 120 tgtaccatcc attgtagcac gtgtgtagcc caggtcataa ggggcatgat gatttgacgt 180 cgtccccacc ttcctccggt ttgtcaccgg cagtctcact agagtgccca acttaatgct 240 ggcaactagt aataagggtt gcgctcgttg cgggacttaa cccaacatct cacgacacga 300 gctgacgaca accatgcacc acctgtcatt ctgtccccga agggaacctc taatctctta 360 gactgtcaga agatgtcaag acctggtaag gttcttcgcg tagcttcgaa ttaaaccaca 420 tgctccaccg cttgtgcggg cccccgtcaa ttcttttgag tttcaacctt gcggtcgtac 480 tccccaggcg gattacttaa tgcgttagct gcagcactga agggcggaaa ccctccaaca 540 cttagtaatc atcgtttacg gcatggacta ccagggtatc taatcctgtt cgctacccat 600 gctttcgagc ctcagcgtca gttgcagacc agacagccgc cttcgccact ggtgttcttc 660 catatatcta cgcatttcac cgctacacat ggagttccac tgtcctcttc tgcactcaag 720 tctcccagtt tccaatgcac ttcttcggtt gagccgaagg ctttcacatt agacctaaaa 780 gccgcctgc gctcgcttta cgcccaataa atccggataa cgcttgccac ctacgtatta 840 ccgcggctgc tggcacgtag ttagccgtgg ctttctggtt aaataccgtc actgggtaaa 900 cagttactct tacccacgtt cttctttaac aacagagctt tacgagccga aacccttctt 960 cactcacgcg gcgttgctcc atcagacttg cgtccattgt ggaagattcc ctactgctgc 1020 ctcccgtagg agtctgggcc gtgtctcagt cccaatgtgg ccgattaccc tctcaggtcg 1080 gctacgtatc actgccttgg tgagccttta cctcaccaac tagctaatac gccgcgggtc 1140 catccagaag tgatagcaga gccatctttt aaaagaaaac catgcggttt tctctgttat 1200 acggtattag catctgtttc caggtgttat cccctacttc tgggcaggtt acccacgtgt 1260 tactcacccg ttcgccactc acttcgtgtt aaaatctcaa tcagtacaag tacgtcataa 1320 tcaattaacg gaagttcgtt cgacttgcat gtattaggca cgccgccagc gttcatcctg 1380 agccatgatc aaactctgtc gt 1402 <210> 3 <211> 1532 <212> DNA <213> Lactobacillus pentosus KF340 16S rDNA <400> 3 cagagtttga tcatggctca ggacgaacgc tggcggcgtg cctaatacat gcaagtcgaa 60 cgaactctgg tattgattgg tgcttgcatc atgatttaca tttgagtgag tggcgaactg 120 gtgagtaaca cgtgggaaac ctgcccagaa gcgggggata acacctggaa acagatgcta 180 ataccgcata acaacttgga ccgcatggtc cgagtttgaa agatggcttc ggctatcact 240 tttggatggt cccgcggcgt attagctaga tggtggggta acggctcacc atggcaatga 300 tacgtagccg acctgagagg gtaatcggcc acattgggac tgagacacgg cccaaactcc 360 tacgggaggc agcagtaggg aatcttccac aatggacgaa agtctgatgg agcaacgccg 420 cgtgagtgaa gaagggtttc ggctcgtaaa actctgttgt taaagaagaa catatctgag 480 agtaactgtt caggtattga cggtatttaa ccagaaagcc acggctaact acgtgccagc 540 agccgcggta atacgtaagg tggcaagcgt tgtccggatt tattgggcgt aaagcgagcg 600 caggcggttt tttaagtctg atgtgaaagc cttcggctca accgaagaag tgcatcggaa 660 actgggaaac ttgagtgcag aagaggacag tggaactcca tgtgtagcgg tgaaatgcgt 720 agatatatgg aagaacacca gtggcgaagg cggctgtctg gtctgtaact gacgctgagg 780 cttcgaaaag tatgggtcgc aaacaggatt agataccctg gtagtccata ccgtaaacga 840 tgaatgctaa gtgttggagg gtttccgccc ttcagtgctg cagctaacgc attaagcatt 900 ccgcctgggg agtacggccg caaggctgaa actcaaagga attgacgggg gcccgcacaa 960 gcggtggagc atgtggttta attcgaagct acgcgaagaa ccttaccagg tcttgacata 1020 ctatgcaaat ctaagagatt agacgttccc ttcggggaca tggatacagg tggtgcatgg 1080 ttgtcgtcag ctcgtgtcgt gagatgttgg gttaagtccc gcaacgagcg caacccttat 1140 tatcagttgc cagcattaag ttgggcactc tggtgagact gccggtgaca aaccggagga 1200 aggtggggat gacgtcaaat catcatgccc cttatgacct gggctacaca cgtgctacaa 1260 tggatggtac aacgagttgc gaactcgcga gagtaagcta atctcttaaa gccattctca 1320 gttcggattg taggctgcaa ctcgcctaca tgaagtcgga atcgctagta atcgcggatc 1380 agcatgccgc gggtgaatac gttcccgggc cttgtacaca ccgcccgtca caccatgaga 1440 gtttgtaaca cccaaagtcg gtggggtaac cttttaggaa ccagccgcct aacgtgggac 1500 agatgattag ggtgaagtcg taacaaggta cc 1532 <210> 4 <211> 1458 <212> DNA <213> Bacillus amyloliquefaciens 26N 16S rDNA <400> 4 ggccatgcgg catgcctata ctgcaagtcg agcggacaga tgggagcttg ctccctgatg 60 ttagcggcgg acgggtgagt aacacgtggg taacctgcct gtaagactgg gataactccg 120 ggaaaccggg gctaataccg gatggttgtt tgaaccgcag ggttcagaca taaaaggtgg 180 cttcggctac cacttacaga tggacccgcg gcgcattagc tagttggtga ggtaacggct 240 caccaaggcg acgatgcgta gccgacctga gagggtgatc ggccacactg ggactgagac 300 acggcccaga ctcctacggg aggcagcagt agggaatctt ccgcaatgga cgaaagtctg 360 acggagcaac gccgcgtgag tgatgaaggt tttcggatcg taaagctctg ttgttaggga 420 agaacaagtg ccgttcaaat agggcggcac cttgacggta cctaaccaga aagccacggc 480 taactacgtg ccagcagccg cggtaatacg taggtggcaa gcgttgtccg gaattattgg 540 gcgtaaaggg ctcgcaggcg gtttcttaag tctgatgtga aagcccccgg ctcaaccggg 600 gagggtcatt ggaaactggg gaacttgagt gcagaagagg agagtggaat tccacgtgta 660 gcggtgaaat gcgtagagat gtggaggaac accagtggcg aaggcgactc tctggtctgt 720 aactgacgct gaggagcgaa agcgtgggga gcgaacagga ttagataccc tggtagtcca 780 cgccgtaaac gatgagtgct aagtgttagg ggggtttccg ccccttagtg ctgcagctaa 840 cgcattaagc actccgcctg ggggagtacg gtcgcaagac tgaaactcaa aggaattgac 900 gggggcccgc acaagcggtg gagcatgtgg tttaattcga agcaacgcga agaaccttac 960 caggtcttga catcctctga caatcctaga agataggacg tccccttcgg gggcagagtg 1020 acaggtggtt gcatggttgt cgtcagctcg tgtcgtgaga tgtttgggtt aagtcccgca 1080 acgagcgcaa cctttgatct tagttgccag cattcagttg ggcactctaa aggtgactgc 1140 cggtgacaaa ccgaaggaaa gggtggggga tgaagttcaa atcatcatgg ccccttattg 1200 acctgggggt aaccaccttg cttccaatgg gacagaaaaa aaaggggggc cgaaaccccc 1260 cggggttaag ccaatcccca caaatttgtt ttcttgtttc ggaaaccaaa ctttgcaatt 1320 ccaccggcgt gaagttggaa taccttttaa ttcccgggat aaccaatgcc cccggggaaa 1380 aacatttccc gggcccttgg caaacccgcc gggtcccacc ccccaagttt gtgtacccca 1440 caagtcgggg gagggacc 1458 <210> 5 <211> 1443 <212> DNA <213> Lactobacillus paracasei 698 16S rDNA <400> 5 gggtgttaca aactctcatg gtgtgacggg cggtgtgtac aaggcccggg aacgtattca 60 acccgcggcg tgctgatccg cgattactag cgattccgac ttcgtgtagg cgagttgcag 120 cctacagtcc gaactgagaa tggctttaag agattagctt gacctcgcgg tctcgcaact 180 cgttgtacca tccattgtag cacgtgtgta gcccaggtca taaggggcat gatgatttga 240 cgtcatcccc accttcctcc ggtttgtcac cggcagtctt actagagtgc ccaactaaat 300 gctggcaact agtcataagg gttgcgctcg ttgcgggact taacccaaca tctcacgaca 360 cgagctgacg acaaccatgc accacctgtc attttgcccc cgaaggggaa acctgatctc 420 tcaggtgatc aaaagatgtc aagacctggt aaggttcttc gcgttgcttc gaattaaacc 480 acatgctcca ccgcttgtgc gggcccccgt caattccttt gagtttcaac cttgcggtcg 540 tactccccag gcggaatgct taatgcgtta gctgcggcac tgaagggcgg aaaccctcca 600 acacctagca ttcatcgttt acggcatgga ctaccagggt atctaatcct gttcgctacc 660 catgctttcg agcctcagcg tcagttacag accagacagc cgccttcgcc actggtgttc 720 ttccatatat ctacgcattt caccgctaca catggagttc cactgtcctc ttctgcactc 780 aagtttccca gtttccgatg cgcttcctcg gttaagccga gggctttcac atcagactta 840 aaaaaccgcc tgcgctcgct ttacgcccaa taaatccgga taacgcttgc cacctacgta 900 ttaccgcggc tgctggcacg tagttagccg tggctttctg gttggatacc gtcacgccga 960 caacagttac tctgccgacc attcttctcc aacaacagag ttttacgacc cgaaagcctt 1020 cttcactcac gcggcgttgc tccatcagac ttgcgtccat tgtggaagat tccctactgc 1080 tgcctcccgt aggagtttgg gccgtgtctc agtcccaatg tggccgatca acctctcagt 1140 tcggctacgt atcatcgcct tggtgagcca ttacctcacc aactagctaa tacgccgcgg 1200 gtccatccaa aagcgatagc ttacgccatc tttcagccaa gaaccatgcg gttcttggat 1260 ctatgcggta ttagcatctg tttccaaatg ttatccccca cttaagggca ggttacccac 1320 gtgttactca cccgtccgcc actcgttcca tgttgaatct cggtgcaagc accgatcatc 1380 aacgagaact cgttcgactt gcatgtatta ggcacgccgc cagcgttcat cctgagccat 1440 gat 1443

Claims (19)

A strain of Lactococcus lactis KF140 (Accession No. KCCM 11673P), a strain of Pediococcus pentosaceus KF159 (Accession No. KCCM 11674P), a strain of Lactobacillus pentosus KF340 (Accession No. KCCM 11675P), Bacillus amyloliquefaciens 26N (Accession No. KCCM 11287P), and Lactobacillus paracasei 698 (Accession No. KFCC 11569P) from the group consisting of Bacillus amyloliquefaciens 26N (Accession No. KCCM 11675P), Bacillus amyloliquefaciens 26N A pharmaceutical composition for preventing or treating allergies comprising two or more selected mixed strains or a culture of said mixed strains as an effective ingredient.
The method according to claim 1,
Characterized in that the mixed strain comprises a strain of Pediococcus pentosaceus KF159 (accession number KCCM 11674P) and a strain of Lactobacillus pentosus KF340 (accession number KCCM 11675P). A pharmaceutical composition.
The method according to claim 1,
The mixed strain is a strain of Pediococcus pentosaceus KF159 (Accession No. KCCM 11674P), a strain of Lactobacillus pentosus KF340 (Accession No. KCCM 11675P), and a strain of Bacillus amyloliquefaciens 26N ( Bacillus amyloliquefaciens 26N) strain (Accession No. KCCM 11287P).
The method according to claim 1,
The mixed strains include Lactococcus lactis KF140 strain (Accession No. KCCM 11673P), Pediococcus pentosaceus KF159 strain (Accession No. KCCM 11674P), Lactobacillus pentosaceus KF340 ( Lactobacillus sp. pentosus KF340) (Accession No. KCCM 11675P), and Bacillus amyloliquefaciens 26N (Accession No. KCCM 11287P).
The method according to claim 1,
The mixed strains include Lactococcus lactis KF140 strain (Accession No. KCCM 11673P), Pediococcus pentosaceus KF159 strain (Accession No. KCCM 11674P), Lactobacillus pentosaceus KF340 ( Lactobacillus sp. pentosus KF340) strain (accession No. KCCM 11675P), Bacillus amyl Lori kwipe sieon bus 26N (Bacillus amyloliquefaciencs 26N) strain (accession No. KCCM 11287P), and Lactobacillus para casei 698 (Lactobacillus paracasei 698) strain (accession No. KFCC 11569P) &Lt; / RTI &gt;
The method according to claim 1,
Wherein the composition inhibits diarrhea reaction, anaphylactic reaction, and rectal temperature decrease due to food allergy.
The method according to claim 1,
Wherein said composition inhibits the production of immunoglobulin E (IgE).
The method according to claim 1,
Wherein said composition inhibits Th2-associated cytokine and Th17-associated cytokine production.
The method according to claim 1,
Lt; RTI ID = 0.0 &gt; Th1 &lt; / RTI &gt; associated cytokine production.
A strain of Lactococcus lactis KF140 (Accession No. KCCM 11673P), a strain of Pediococcus pentosaceus KF159 (Accession No. KCCM 11674P), a strain of Lactobacillus pentosus KF340 (Accession No. KCCM 11675P), Bacillus amyloliquefaciens 26N (Accession No. KCCM 11287P), and Lactobacillus paracasei 698 (Accession No. KFCC 11569P) from the group consisting of Bacillus amyloliquefaciens 26N (Accession No. KCCM 11675P), Bacillus amyloliquefaciens 26N Or a mixture of two or more selected strains or a culture of said mixed strain as an active ingredient.
11. The method of claim 10,
Characterized in that the mixed strain comprises a strain of Pediococcus pentosaceus KF159 (accession number KCCM 11674P) and a strain of Lactobacillus pentosus KF340 (accession number KCCM 11675P). Health functional food composition.
11. The method of claim 10,
The mixed strain is a strain of Pediococcus pentosaceus KF159 (Accession No. KCCM 11674P), a strain of Lactobacillus pentosus KF340 (Accession No. KCCM 11675P), and a strain of Bacillus amyloliquefaciens 26N ( Bacillus amyloliquefaciens 26N) strain (Accession No. KCCM 11287P).
11. The method of claim 10,
The mixed strains include Lactococcus lactis KF140 strain (Accession No. KCCM 11673P), Pediococcus pentosaceus KF159 strain (Accession No. KCCM 11674P), Lactobacillus pentosaceus KF340 ( Lactobacillus sp. pentosus KF340) (Accession No. KCCM 11675P), and Bacillus amyloliquefaciens 26N (Accession No. KCCM 11287P).
11. The method of claim 10,
The mixed strains include Lactococcus lactis KF140 strain (Accession No. KCCM 11673P), Pediococcus pentosaceus KF159 strain (Accession No. KCCM 11674P), Lactobacillus pentosaceus KF340 ( Lactobacillus sp. pentosus KF340) strain (accession No. KCCM 11675P), Bacillus amyl Lori kwipe sieon bus 26N (Bacillus amyloliquefaciencs 26N) strain (accession No. KCCM 11287P), and Lactobacillus para casei 698 (Lactobacillus paracasei 698) strain (accession No. KFCC 11569P) &Lt; / RTI &gt;
11. The method of claim 10,
Wherein the composition inhibits diarrhea reaction, anaphylactic reaction, and rectal temperature decrease due to food allergy.
11. The method of claim 10,
Wherein the composition inhibits the production of immunoglobulin E (IgE).
11. The method of claim 10,
Wherein said composition inhibits Th2-related cytokine and Th17-related cytokine production.
11. The method of claim 10,
Lt; RTI ID = 0.0 &gt; Th1 &lt; / RTI &gt; associated cytokine production.
A strain of Lactococcus lactis KF140 (Accession No. KCCM 11673P), a strain of Pediococcus pentosaceus KF159 (Accession No. KCCM 11674P), a strain of Lactobacillus pentosus KF340 (Accession No. KCCM 11675P), Bacillus amyloliquefaciens 26N (Accession No. KCCM 11287P), and Lactobacillus paracasei 698 (Accession No. KFCC 11569P) from the group consisting of Bacillus amyloliquefaciens 26N (Accession No. KCCM 11675P), Bacillus amyloliquefaciens 26N A cosmetic composition for improving allergies comprising two or more selected mixed strains or a culture of said mixed strains as an active ingredient.

Images